-5%
Mirogabalin belongs to the gamma amino acid derivative class. It works by selectively binding to the α2δ subunits of voltage-gated calcium channels (VGCCs). This action reduces calcium influx into nerve cells, thereby decreasing neurotransmitter release from presynaptic neurons. As a result, it helps reduce the overactivity of neurons in the central nervous system (CNS), which is responsible for neuropathic pain.
After oral administration, Mirogabalin is rapidly absorbed, reaching peak plasma levels within approximately 0.5 to 1.5 hours. It has low protein binding (~25%) and a distribution volume of around 64–88 L. The drug is primarily eliminated unchanged through the kidneys (61–72%) via filtration and active secretion, while a small portion (13–20%) undergoes hepatic metabolism. Its elimination half-life ranges from about 2 to 4.9 hours, with nearly 99% excreted in urine and only about 1% in feces.
Mirogabalin Besylate tablets are prescribed for the management of various types of nerve-related pain, including:
- Neuropathic pain
- Diabetic peripheral neuropathic pain (DPNP)
- Postherpetic neuralgia (PHN)
- Peripheral neuropathic pain (PNP)
